Advertisement · 728 × 90
#
Hashtag
#majestec3
Advertisement · 728 × 90
@hemehub.bsky.social
1 month ago
Post image Post image Post image Post image

🩸🔬 Today’s questions!

Swipe to see the answers and their explanations!

#MultipleMyeloma #MajesTEC3 #Teclistamab #BispecificAntibodies #StepUpDosing #Immunotherapy #IVIG #HematologyOncology #Oncology #MedEd #ClinicalTrials #HEMEHUB

2 0 0 0
@hemehub.bsky.social
1 month ago
Post image Post image

🩸📊Today’s question highlights long-term outcomes from the MajesTEC-3 trial.

See the answer and explanation on the next slide!

#MultipleMyeloma #MedEd #Hematology #Teclistamab #Daratumumab #BispecificAntibodies #ClinicalTrials #HemeOnc #MedEd #MajesTEC3 #HEMEHUB

0 0 0 0
@hemehub.bsky.social
1 month ago
Video

🩸 Additional insights on adverse events and management in Multiple Myeloma

#MultipleMyeloma #BCMA #GPRC5D #BispecificAntibodies #BsAbs #Immunotherapy #PlasmaCells #IVIG #Oncology #HemOnc #Hematology #ClinicalTrials #MajesTEC3 #HEMEHUB

0 0 0 0
@hemehub.bsky.social
1 month ago
Video

🩸Facts about Multiple Myeloma:

Adverse Events and Management

#CRS #ICANS #Neurotoxicity #Neutropenia #Teclistamab #MajesTEC3 #Immunotherapy #Tocilizumab #Hematology #RareDiseases #BloodDisorders #ClinicalInsights #MedEd #HEMEHUB

1 0 0 0
Myeloma Patients Europe
Myeloma Patients Europe
@myelomaeurope.bsky.social
4 months ago
ASH25 | Majestec-3 trial
ASH25 | Majestec-3 trial YouTube video by Myeloma Patients Europe

Probably the most important data in #myeloma was presented today #ASH25. @_DrCP explains in this video the main results of #majestec3 trial looking at the combination of daratumumab and teclistamab in #RRMM
youtu.be/LEFWII_tnsc?...

0 0 0 0